Rekombinanter Integrin beta 7 Antikörper

Produktnummer ABIN7881207

Der Kaninchen Monoklonal anti-Integrin beta 7 Antikörper wird verwendet zum Nachweis von Integrin beta 7 in Proben von Human. Er wurde validiert für WB.

Kurzübersicht für Rekombinanter Integrin beta 7 Antikörper (ABIN7881207)

Target: Integrin beta 7 (ITGB7)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser Integrin beta 7 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Klon: 32I45

Produktdetails anti-Integrin beta 7 Antikörper

Verwendungszweck: ITGB7 Antibody / Integrin beta 7

Aufreinigung: Affinity-chromatography

Immunogen: A synthesized peptide derived from human Integrin beta 7 was used as the immunogen for the ITGB7 antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the ITGB7 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store the ITGB7 antibody at -20oC.

Details zu Integrin beta 7

Target: Integrin beta 7 (ITGB7)

Andere Bezeichnung: ITGB7

Hintergrund: ITGB7 antibody detects integrin beta 7, a transmembrane receptor subunit encoded by the ITGB7 gene. Integrins are heterodimeric receptors composed of alpha and beta chains that mediate cell adhesion, migration, and signaling. Integrin beta 7 pairs with alpha 4 or alpha E chains to form integrin alpha4beta7 and integrin alphaEbeta7. These receptors are critical for immune cell trafficking, mucosal homing, and lymphocyte adhesion to epithelial cells.

ITGB7 antibody is widely applied in immunology and inflammation research. Integrin alpha4beta7 directs lymphocytes to gut associated lymphoid tissues by binding to MAdCAM 1 on endothelial cells, while integrin alphaEbeta7 binds to E cadherin, supporting retention of lymphocytes in epithelial layers. By detecting ITGB7, researchers can study how integrins regulate lymphocyte homing and immune surveillance in mucosal tissues.

In flow cytometry, ITGB7 antibody quantifies surface expression on lymphocytes, distinguishing subsets involved in mucosal immunity. Immunohistochemistry maps ITGB7 expression in gut and lymphoid tissues, while immunofluorescence highlights cell surface localization. Western blotting detects integrin beta 7 protein in immune cell lysates, providing complementary analysis across platforms.

ITGB7 is a therapeutic target in inflammatory bowel disease. Antibodies blocking integrin alpha4beta7 reduce lymphocyte trafficking to the gut and alleviate inflammation. Altered ITGB7 expression is also observed in autoimmune diseases and certain cancers, linking it to pathogenesis. By applying ITGB7 antibody, scientists can explore integrin biology in health and disease and evaluate therapeutic strategies targeting lymphocyte migration.

Beyond mucosal immunity, integrin beta 7 contributes to immune responses in reproductive tissues, respiratory mucosa, and skin. It also participates in cytotoxic lymphocyte interactions with epithelial cells, influencing immune defense and tolerance. ITGB7 antibody therefore supports a wide range of studies in immunology, oncology, and inflammation.

ITGB7 antibody from NSJ Bioreagents delivers reliable specificity for detecting integrin beta 7 across multiple methods. Its performance supports both basic research and translational studies into immune cell trafficking and integrin targeted therapies.

UniProt: P26010

Pathways: Integrin Complex